Evidence-based pharmacological treatment of generalized anxiety disorder
Open Access
- 7 January 2011
- journal article
- review article
- Published by Oxford University Press (OUP) in International Journal of Neuropsychopharmacology
- Vol. 14 (05) , 697-710
Abstract
Generalized anxiety disorder (GAD) is common in community and clinical settings. The associated individual and societal burden is substantial, but maKeywords
This publication has 82 references indexed in Scilit:
- E.01.03 Antipsychotics in anxiety disordersEuropean Neuropsychopharmacology, 2008
- The generalized anxiety spectrum: prevalence, onset, course and outcomeEuropean Archives of Psychiatry and Clinical Neuroscience, 2008
- Resolution of sexual dysfunction during acute treatment of major depression with milnacipranHuman Psychopharmacology: Clinical and Experimental, 2008
- Role of pregabalin in the treatment of generalized anxiety disorderNeuropsychiatric Disease and Treatment, 2007
- Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetineJournal of Psychopharmacology, 2006
- Discontinuation symptoms in depression and anxiety disordersInternational Journal of Neuropsychopharmacology, 2005
- Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for PsychopharmacologyJournal of Psychopharmacology, 2005
- Prevention of relapse in generalized anxiety disorder by escitalopram treatmentInternational Journal of Neuropsychopharmacology, 2005
- Sexual dysfunction associated with antidepressant drugsExpert Opinion on Drug Safety, 2004
- Efficacy of Sertraline in a 12-Week Trial for Generalized Anxiety DisorderAmerican Journal of Psychiatry, 2004